Tools   Select Another Resource Report Type

http://molonc.bccrc.ca/platforms/btb/

The Molecular Oncology department hosts the breast cancer tumour tissue repository (BREAST-TTR), a project within the agency-wide tumour tissue repository. The BREAST-TTR comprises several important banks of breast tissues, contemporaneous as well as archival. The main banks are: * 3000 frozen breast cancers, linked to 15 year outcomes data from the BCCA Breast Cancer Outcomes Unit. This archival bank consists of frozen tissue, DNA and RNA, and a tissue microarray of the cases. * Live-cryopreserved cancers. At present around 50 individual cases of metastatic breast cancer, with tumour material cryopreserved for subsequent cell culture/xenograft work. * Comptemporary bank. Between the TTR in Victoria and the accrual site in Vancouver, approximately 1300 contemporaneous (within last 4 years) breast cancers with matched normal DNA and outcomes linkages.

Proper citation: British Columbia Breast Cancer Tumour Bank (RRID:SCR_006671) Copy   

•   Source: SciCrunch Registry

http://ncrad.iu.edu/

Cell repository for Alzheimer's disease that collects and maintains biological specimens and associated data. Its data is derived from large numbers of genetically informative, phenotypically well-characterized families with multiple individuals affected with Alzheimer's disease, as well as individuals for case-control studies.

Proper citation: National Cell Repository for Alzheimer's Disease (RRID:SCR_007313) Copy   

•   Source: SciCrunch Registry

http://www.nia.nih.gov/research/nonhuman-primate-tissue-bank-handbook

A repository of tissue collected from nonhuman primate (NHP) species under contractual arrangement with Wisconsin National Primate Research Center (WI NPRC). NIA''''s Nonhuman Primate Tissue Bank collects and archives tissue from necropsies performed at primate centers nationwide. The goal is to collect various tissues from aged monkeys with smaller amounts of the same tissues from young and middle-aged monkeys. Tissue will be provided as: (1) fresh frozen, stored at ����?��������??80 degrees Celsius; (2) formalin fixed; or (3) fresh frozen tissue in OCT medium.Most frozen tissues are provided in approximately 1 gram of tissue per vial. Fixed tissue is available as slides (sections) from paraffin-embedded blocks. Slides can be stained if requested. Tissue from NIA''''s Nonhuman Primate Tissue Bank is available to investigators at academic and nonprofit research institutions who are engaged in funded research on aging. The project name and funding source must accompany all orders. The NIA will not be able to ship non-human primate tissue outside of the United States or US territories. Investigators at for-profit entities are not eligible to purchase tissue from NIA''''s Nonhuman Primate Tissue Bank unless it is for a Small Business Innovation Research grant from NIA. NIA provides the health information as given by the donor site and cannot guarantee other aspects of the health status not explicitly stated in the Vital Statistics Information Sheet. Concerns about the specific health status of donor animals should be indicated on the order form.

Proper citation: NIA Nonhuman Primate Tissue Bank (RRID:SCR_007324) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.istge.it/cldb/indexes.html

Hypertext on cell culture availability extracted from the Cell Line Data Base of the Interlab Project. HyperCLDB includes links to records of OMIM, the Online Mendelian Inheritance in Man Catalogue, and now also links to the PubMed, database of bibliographic biomedical references, which are drawn primarily from MEDLINE and PREMEDLINE.

Proper citation: Hyper Cell Line Database (RRID:SCR_007730) Copy   

•   Source: SciCrunch Registry

http://www.nccc.com

Provides access to large scale cell culture at reasonable cost. The Cell Culture Center has experience with the production of over 1700 cell lines. Numerous common cell lines, such as HeLa, CHO, 293, BHK, and hybridomas are routinely produced at the Center. We will adapt your cell line or custom protocol to large scale production then deliver the cells in the quantity and frequency you need. Large Scale Production Services: Mammalian cells: Suspension culture (1 to 400 liters per day), Anchorage dependent culture (1 to 200 roller bottles per batch), Purified monoclonal antibodies (10 mg to 100 grams), Non-hybridoma cell secreted proteins, Conditioned media Secreted proteins from suspension cultures can be produced in automated hollow fiber bioreactor systems. These systems may be considered after initial static culture production yields are determined. Upon determining the quantities requested by the investigator, the appropriate automated system will be used. For more information on the automated instrumentation available for the use of secreted protein production, please refer to the Biovest International web page (www.biovest.com). Working with our experienced personnel and quality controlled, state-of-the-art facilities also permits access to large quantities of cells or protein so you aren''t limited by the cell culture capacities of your own laboratory. The Center fulfills the needs of small research laboratories as well as those of larger institutions. Customers from all sectors of the research and industrial community are welcome to inquire about our services. If you''d like to inquire about using our services, use the contact infromation below. Key words: Cell, cells, culture, monoclonal, antibodies, antibody.

Proper citation: National Cell Culture Center (RRID:SCR_013467) Copy   

•   Source: SciCrunch Registry

http://www.emdbiosciences.com

A commercial antibody company.

Proper citation: EMD4Biosciences (RRID:SCR_008441) Copy   

•   Source: SciCrunch Registry

http://www.fisherbioservices.com/

Biological material management services provider including biospecimen storage, biobanking services, specimen collection kits, sample processing, DNA /RNA extraction and amplification, sample storage, distribution, and clinical trial support. They also offer transport and storage of active pharmaceutical ingredient(s) (API and bio-API), including cryogenic. They can assist with public health research, phase I???????????????IV studies, prospective and retrospective studies, IND/NDA submissions to the FDA, and entry of biotherapeutics into the commercial marketplace.

Proper citation: Fisher BioServices (RRID:SCR_010528) Copy   

•   Source: SciCrunch Registry

http://www.surgicalbio.com

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 2nd, 2022. Tissue bank and service organization for bioimplants.

Proper citation: Surgical Biologics - a MiMedx Group Company (RRID:SCR_010661) Copy   

•   Source: SciCrunch Registry

http://www.abh.com

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 2nd, 2022. Manufacturer of Dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process.

Proper citation: Advanced Biohealing, Inc. (RRID:SCR_010630) Copy   

•   Source: SciCrunch Registry

http://www.ibmt.fraunhofer.de/en.html

Institute that acts as device and technology developer when it comes to the solution of individual research and development projects and tasks from the areas of biomedical / medical engineering, molecular and cellular biotechnology, biohybrid technology, cryo(bio)technology and nano(bio)technology, ultrasound technology, neuroprosthetics / implants, (mobile) laboratory technology, sensor and measurement technology, health telematics, environmental control systems, material testing, home systems, air quality control and security systems as well as laboratory automation including in-line / on-line process control. The institute works in the field of stem cell research and hosts extensive cell line stocks in industrial and clinically structured biobanks for low temperature storage of valuable samples (fluids, cells, tissue fragments).

Proper citation: Fraunhofer Institute for Biomedical Engineering (RRID:SCR_011236) Copy   

•   Source: SciCrunch Registry

http://www.capitalbiosciences.com/

Biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems and others as well as services like Custom Recombinant Adenovirus Production, Custom Recombinant Lentivirus Production, Protein Detection and Quantification and Stable Cell Line Production for academic and governmental research institutes, pharmaceutical and biotechnology industry. Capital Biosciences offers most types of human tissues, normal and diseased, with extensive clinical history and follow up information. Standard specimen format: Snap-frozen(flash-frozen), Formalin fixed and paraffin embedded (FFPE) tissues, Blood and blood products, Bone marrow, Total RNA, Genomic DNA, Total Proteins, Primary cell cultures, Viable frozen tissue. Tumor tissue samples include: Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck (H&N) Carcinoma, Hepatocellular Carcinoma (HCC), Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell (NCSLC), Lung Cancer, Small Cell (SCLC), Melanoma, Mesothelioma, non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer.

Proper citation: Capital Biosciences (RRID:SCR_004879) Copy   

•   Source: SciCrunch Registry

http://www.meduniwien.ac.at/kin/index.html

The (Clinical) Institute of Neurology (IN) of the Medical University Vienna was founded in 1882 by Heinrich Obersteiner. It is the oldest institution embracing the multidisciplinarity of neurosciences and has served as model for the establishment of similarly designed institutions in many countries. The original location of the then Neurological Institute in Vienna was at Schwarzspanierstrasse. Since 1993, IN is located in the Vienna General Hospital in top-class laboratory facilities. IN is committed to its proud tradition as Obersteiner Institute and to a promising future of a nationally and internationally leading institution in the clinical neurosciences. Our work aims to translate the understanding of nervous diseases to the development of novel therapeutics and diagnostics. IN''''s tasks include diagnostic patient service, research and graduate / postgraduate teaching in neuropathology, neurochemistry, and neuro-molecular biology in an integrated way. Neuropathology is a recognized medical specialty in Austria. It analyzes structural changes of nervous tissues in disease. Diagnostic neuropathology makes use of most modern morphological techniques applied to diseased central, peripheral and vegetative nervous tissues and fluids, and muscle. Neuropathological diagnoses are a basis for disease classification and rational therapies. Neurodegenerative disorders, in particular prion diseases, virus diseases affecting the nervous system, and brain tumors (neuro-oncology) are research priorities. In the highly publicized area of prion diseases, IN has developed into a national and international center of excellence and expertise that leads several European, EU-funded networks in prion research. As an indispensable asset, the IN possesses a large brain bank that has systematically collected neuropathological specimens since 1948. Most samples are fixed and paraffin-embedded tissue only, but in a part of neurosurgical, nerve and muscle biopsies and autopsies, also fresh tissue is obtained, frozen and stored at -80 degrees C. Occasionally blood and CSF are also available. The unique neuropathological collection of histological slides, paraffin blocks and formol-fixed nervous tissues now comprises about 16.000 brain autopsies, 30.000 neurosurgical and 7.500 nerve/muscle biopsies. Also a number of cell cultures have been stored, mainly fibroblasts from patients with rare neurometabolic diseases, and primary cultures of brain tumors. IN participates in the EU-supported European Network of Brain Banks BrainNet Europe.

Proper citation: Medical University of Vienna Institute of Neurology (RRID:SCR_005030) Copy   

•   Source: SciCrunch Registry

http://www.kaly-cell.com/

Commercial organization that offers human and animal hepatocyte products as well as other products derived from liver tissue, kits and media. Services they offer include in vitro metabolism, in vitro toxicology and cell therapy.

Proper citation: KaLy-Cell (RRID:SCR_003963) Copy   

•   Source: SciCrunch Registry

http://www.cellartis.com/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021. Company focusing on stem cell derived products and services for drug discovery, toxicity testing and applications within regenerative medicine. The company leverages long-standing experience in stem cell handling and scale up together with leading expertise in differentiation of cells into mature and functional human cells. The laboratories are prepared to meet the EU and US guidelines for current Good Manufacturing Practice (cGMP). Now part of Takara Bio Inc.

Proper citation: Cellartis (RRID:SCR_003960) Copy   

•   Source: SciCrunch Registry

http://www.origene.com.cn/

A commercial antibody vendor.

Proper citation: Origene China (RRID:SCR_004436) Copy   

•   Source: SciCrunch Registry

http://www.tissuenet.com/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on August 17,2021. Manufacturer of allograft tissue grafts in the United States in the ortho-biologics field of medicine. They develop new products for the patients they serve, including the UltraGraft non-irradiated & sterile line of allograft tissue implants., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: TissueNet (RRID:SCR_004489) Copy   

•   Source: SciCrunch Registry

http://www.bioreclamationivt.com/

BioIVT, formerly BioreclamationIVT, is global provider of biological specimens and services. Provides biological and in vitro products specializing in control and disease state matrices manufactured from human and animal whole blood, plasma, serum, tissues and other fluids which are used in drug discovery, compound development, clinical and research diagnostics., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Bioreclamation (RRID:SCR_004728) Copy   

•   Source: SciCrunch Registry

http://www.phenogenomics.ca/

The Toronto Centre for Phenogenomics (TCP) is an innovative, scientific collaboration between four research hospitals to operate a centralized, state-of-the-art research-enabling mouse facility. We conduct and support genetic research involving generation of mutant mice, physiological phenotyping, behavioural analysis, imaging, pathology and cryopreservation for storage and distribution. This joint project involving Mount Sinai Hospital, The Hospital for Sick Children, University Health Network and St. Michael''s Hospital pools resources and expertise to achieve excellence and economies of scale. The TCP opened for operations in October 2007. The centre functions as a regional, national and international resource for mouse models of human disease. This 120,000 square foot facility is located at 25 Orde Street, Toronto, and occupies four floors two below ground and two above. It houses specialized laboratories for mouse generation and analysis and, when fully occupied, it will contain approximately 36,000 cages (180,000 mice). The world-renowned scientific staff studies mammalian gene function, identifies genetic components of complex human disease, produces new mouse models of human disease, develops and tests new cell-based and gene-based therapies, and develops technologies for genome manipulation and phenotypic analysis. The TCP offers state-of-the-art mouse holding and facility support services to academic stakeholders and strategic private sector partners. It houses the Centre for Modeling Human Disease (CMHD), the Canadian Mouse Mutant Repository (CMMR), and the Mouse Imaging Centre (MICe) to provide an array of pre-clinical research services to clients. TCP Services * Phenotyping * Genetic Mapping * Pathology * Cryopreservation * Imaging * Genetically Engineered Mouse Models * Mouse Holding and Technical Services

Proper citation: Toronto Centre for Phenogenomics (RRID:SCR_006143) Copy   

•   Source: SciCrunch Registry

http://www.ms-research.dk/genetics.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. We have collected DNA for more than 15 years, and today we have DNA from more than 1,800 Danish MS patients and 1,200 controls, all kept in the Danish Multiple Sclerosis Biobank in DMSC. In order to increase the sample size for genetic testing, we have participated in the Nordic MS Genetic Network since 1994, and today the Nordic material consists of more than 6,000 MS cases and 6,000 controls. The research in DMSC is focused on the candidate gene approaches and the genetic influence on the differences in treatment response. We are part of the IMSGC (International Multiple Sclerosis Genetic Consortium) and the Wellcome Trust Case Control Consortium (WTCCC), where 23 research groups from 15 countries are performing the largest set of MS genome-wide association study (GWAS), genotyping 11,000 cases and 11,000 controls using 500,000 SNP chip. Primary results have elucidated associations to more than 100 gene variations (SNPs). Following this collaboration we are joining the Immunochip Consortium, where 1,000 Danish cases and 1,000 Danish controls participate in a large scale genetic analysis, investigating best genes/regions/SNPs in MS together with other international MS research groups and 9 other autoimmune diseases research groups, looking for shared autoimmune genes. The risk of MS has been increasing over the last 50 years, especially among women older than 40 years. On this background we have initiated a project looking at aspects of gender differences, including different treatment responses. Furthermore, we have initiated a large-scale vitamin D project, investigating gene variations within the vitamin D pathway, and the importance of vitamin D in clinical and immunological disease activity. In addition, we have collected more than 800 questionnaires from MS patients dealing in detail with lifestyle and environmental exposure for a project studying gene-environmental interactions.

Proper citation: Danish Multiple Sclerosis Biobank (RRID:SCR_000089) Copy   

•   Source: SciCrunch Registry

http://www.ucl.ac.uk/biobank/

Two University College London (UCL) biobanks, one based at the Royal Free Hospital (RFH) Campus and the other based at Bloomsbury supporting Pathology and the Cancer Institute, will act as physical repositories for collections of biological samples and data from patients consented at UCLH, Partners Hospitals and external sources. This will incorporate collections of existing stored samples and new collections. UCL-RFH BioBank, the physical repository at the Royal Free, presents a unique opportunity to advance medical research through making access to research tissue easier, faster and much more efficient. The BioBank is both a physical repository, with capacity for up to 1 million cryogenically stored samples and a virtual repository for all tissue, cell, plasma, serum, DNA and RNA samples stored throughout UCLP. In particular, samples considered "relevant material", such as tissues and cells, that are licensed by the Human Tissue Authority, can be stored long term. Existing holdings of tissues and cells where appropriate can be transferred to the Physical BioBank at the Royal Free. UCL - Royal Free BioBank provides a flexible approach to banking, allowing the Depositor to pick and choose services that are tailored to fit their requirements. Collaborations arising from publicizing of the existence of the holdings are entirely at the discretion of the depositor, as the facility ensures that access to the deposits remains at the decision of the Depositor/User. UCL Biobank for studying Health and Disease (based at Pathology-Rockefeller building and the UCL-Cancer Institute will support projects principally involved in the study of human disease. The aim is to support primarily, research in the Pathology Department, UCLH and the UCL-Cancer Institute but it will also support other UCLH partners. The biobank will store normal and pathological specimens, surplus to diagnostic requirements, from relevant tissues and bodily fluids. Stored tissues will include; snap-frozen or cryopreserved tissue, formalin-fixed tissue, paraffin-embedded tissues, and slides prepared for histological examination. Tissues will include resection specimens obtained surgically or by needle core biopsy. Bodily fluids will include; whole blood, serum, plasma, urine, cerebrospinal fluid, milk, saliva and buccal smears and cytological specimens such as sputum and cervical smears. Fine needle aspirates obtained from tissues and bodily cavities (e.g. pleura and peritoneum) will also be collected. Where appropriate the biobank will also store separated cells, protein, DNA and RNA isolated from collected tissues and bodily fluids described above. Some of the tissue and aspirated samples will be stored in the diagnostic archive.

Proper citation: UCL Biobank (RRID:SCR_000517) Copy   

•   Source: SciCrunch Registry